Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Article content
Article content
– Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ('MDD') with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) –
Article content
Article content
– Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities –
Article content
– Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline –
Article content
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.
Article content
'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.'
Article content
Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance.
Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003.
Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline.
Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows:
U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041.
U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004.
Article content
Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics
Article content
Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways.
Article content
The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include:
Article content
In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1
Article content
Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2
Article content
Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3
Article content
President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4
Article content
On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows:
Article content
Panel Title:
Article content
Date and Time:
Article content
About Cybin
Article content
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Article content
With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Article content
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Sources
Article content
NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, https://www.youtube.com/watch?v=KEQFKBME668 (accessed June 9, 2025).
Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, https://www.politico.com/newsletters/future-pulse/2025/05/28/a-psychedelics-hire-at-hhs-00371416 (accessed June 9 2025).
The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, https://www.wsj.com/politics/policy/republican-psychedelic-drug-therapy-fc313ea2 (accessed June 9 2025).
The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, https://apnews.com/article/means-trump-surgeon-general-mushrooms-psychedelic-drugs-72c22ed077409b4bb865214e7ef304a8 (accessed June 9 2025).
Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. https://www.foxnews.com/video/6373914669112
Article content
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
Article content
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Article content
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor & Media:
Article content
Article content
Gabriel Fahel
Article content
Article content
Chief Legal Officer
Article content
Article content
Cybin Inc.
Article content
Article content
Article content
Article content

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CTV News

35 minutes ago

• CTV News

Why one U.S. doctor is moving to Vancouver Island

Dr. Muthana Yacoub has been working as a family physician in Woodland Park, Colo., for six years now. But by November, he will be practising medicine in Colwood, B.C. 'We finally visited this past weekend and we absolutely fell in love with it,' Yacoub said. He'll work at a unique, city-owned clinic, which has recruited four doctors from the U.S., the U.K. and other parts of Canada. Yacoub, who spent part of his childhood living in Toronto, already had Canadian citizenship. He heard about the new Vancouver Island clinic while attending a medical conference in Vancouver last November, and was ready for change. 'You do see this pressure from insurance companies where you feel like you're just kind of catering to their whims and those whims change every six months,' he explained. 'It can be extremely frustrating, because you know what you want to do for the patient, what the right thing to do for the patient is, but you have no efficacy in actually getting that done.' The Ministry of Health is hoping more U.S. doctors feel the same as Yacoub. The province recently began a $5-million recruitment campaign running ads in Washington State, Oregon and parts of California. This week, a branded truck was giving out free coffee to health-care workers in Seattle. 'Doctors of BC supports all efforts to address the province's health workforce challenges,' said Dr. Charlene Lui, the organization's president. 'It's so important to improve timely and quality access to care for our patients.' Lui said Doctors of BC is willing to work with the Ministry of Health and other key partners to 'explore solutions for this very complex issue, including integrating foreign-trained physicians not only from the U.S., but around the globe.' She said they are exploring questions around licensing with stakeholders. The ministry said more than 1,600 health-care providers have expressed an interest in moving to our province. However, despite requests from CTV News, the ministry did not provide any numbers on how many doctors and nurses had actually committed to making the move. In a statement, the ministry said: 'Steps are being taken to get those interested to B.C., but this is a process that takes time.''We are also working with our federal partners on the immigration front,' the statement added. Yacoub said he thinks the biggest barrier for workers coming from the U.S. is 'the concept of moving to a different country and the whole licensing situation.' He also pointed out that America is facing its own family doctor shortage, particularly in rural areas. He said despite flaws in B.C.'s health-care system, he believes it's a much better system than the one he is currently working in. 'Even the poorest among us can get care if they need it, whereas here (in the U.S.), it's a coin toss. They may not get their care at all,' he said, adding that someone should not face bankruptcy to get medical treatment. Yacoub said Colwood has been very welcoming and he can't wait to make B.C. home. 'From the bottom of my heart, thank you,' he said.

CBC

36 minutes ago

• CBC

New totem pole in B.C. acknowledges Canada's legacy of Indian hospitals

Social Sharing An Indigenous community near Prince Rupert, B.C., raised a new memorial totem pole ahead of National Indigenous People's Day to honour those who were affected by the Miller Bay TB Hospital. According to the Lax Kw'alaams Band, the Miller Bay TB Hospital, which operated from 1946 to 1971, was used by the federal government to isolate and treat Indigenous patients with tuberculosis (TB). Many of them were children who were forcibly removed from their communities and patients were often separated from family for years at a time. In a statement, the Lax Kw'alaams Band said Friday's pole raising ceremony was part of a day of remembrance and healing. "We wanted to recognize [and educate] people throughout Canada and B.C. on Miller Bay and the effects that it had on a lot of people," said Joey Wesley, a councillor with Lax Kw'alaams Band. "One way that we wanted to recognize and honour everyone was to carve and raise a totem pole in memory." The pole was carved by Mike Epp, a Tsimshian carver. In a press release, Epp said the monument is made out of red cedar and represents healing for the survivors of Miller Bay TB Hospital. "I can't wait to see how it looks standing up," he said ahead of Friday's event, noting that pole-raising ceremonies bring the community together. The Miller Bay TB Hospital was one of at least three major Indian hospitals that operated in B.C., according to the University of British Columbia's Indian Residential School History and Dialogue Centre. Indian hospitals were substandard facilities operated by the federal government starting in the 1930s to separate Indigenous people from the rest of the Canadian population to stop the spread of tuberculosis. Tens of thousands of First Nations, Inuit and Mé​​​​​tis patients, including children, were admitted to the overcrowded, poorly staffed and unsanitary institutions. Survivors allege they faced physical and sexual abuse from hospital staff, along with forcible confinement to beds without a medical reason. Some say they were also the subject of medical experiments. In March, Ottawa reached a proposed settlement agreement with survivors of Indian hospitals to provide individual compensation ranging from $10,000 to $200,000. Totem pole figure meanings, from bottom to top Epp says that the bottom figure of the totem pole is a shaman. "The shaman is there to help heal the people that are still dealing with their trauma from the hospital," Epp told CBC's Daybreak North. Above the shaman is a figure of a woman chief, who is holding a young man in her hands. "This part represents continuing the traditions, teaching the young people in the tribe how to carry themselves." Four small figures are above the woman chief, representing the people who were lost in the Miller Bay Hospital. On one side are men, on the other side are women. Above that is a foot and a half of blank space where pieces of copper are going to be installed. The copper pieces are being sent to Epp from family members who were impacted. A warrior with copper in one hand, and a spear in another, sits on top of the blank spot. The warrior represents the resilience of First Nations people and their role as guardians of future generations, lands and waters.

Globe and Mail

an hour ago

• Globe and Mail

House approves Bill C-5 to fast-track projects, Carney pledges summer consultations with Indigenous leaders

The House of Commons approved the government's legislation to fast-track big projects Friday before breaking for summer, wrapping up a brief but hectic four-week sitting. Prime Minister Mark Carney marked the event with an evening news conference alongside Indigenous Services Minister Mandy Gull-Masty and other MPs, where he vowed to address Indigenous concerns that the bill would allow Ottawa to override their rights. Mr. Carney laid out a plan for formal summits with Indigenous leaders over the summer to work out the details of how the new project regime will work. He also acknowledged that his government could have done a better job of explaining how the process will ensure Indigenous rights are protected. 'Being a reliable partner to Indigenous peoples is not just about upholding the duty to consult. It's about enabling the creation of long-term wealth and prosperity for Indigenous peoples through full equity ownership,' he said. Carney responds to Indigenous criticism of Bill C-5, says consultation is 'at the heart' of legislation Bill C-5 contains a section that aims to eliminate federal barriers to interprovincial trade and a section that allows the government to list specific large projects as national priorities and then exempt them from various legal requirements to speed up approvals. Mr. Carney said the plan was a central plank of the Liberal platform and pledged that it will be 'the most important economic initiative this country has seen for a long time.' Ms. Gull-Masty, the first Indigenous person to serve as Indigenous Services Minister, said the bill lays out a plan to co-develop projects with Indigenous communities. 'Now the real work begins,' she said. The House of Commons is not scheduled to resume sitting until Sept. 15. But the Indigenous consultations on C-5 are just one of many policy files that will continue to play out over the summer. Canada's 45th Parliament kicked off just a month after the April 28 federal election that returned the Liberals to power with another minority government, this time under Mr. Carney, the party's new leader. Trade tensions with the United States dominated Canadian political debate during the election campaign and that has carried through the early days of the Carney government. Chartrand on Bill C-5: 'We do have to have consent from Indigenous rights holders' The Prime Minister and U.S. President Donald Trump set a 30-day deadline at this week's Group of Seven summit in Kananaskis, Alta., to reach a deal aimed at resolving trade issues between the two countries. Mr. Carney leaves Sunday for Brussels and then The Hague for meetings of the Canada-European Union summit and the North Atlantic Treaty Organization summit. In an interview Friday in Parliament's West Block, Government House Leader Steven MacKinnon said Canadians should not expect Mr. Carney's pace to slow down during the summer. 'I think that we have a Prime Minister who very much is going to be a 365-day-a-year leader of this country,' he said. Further, he said the sheer number of outside issues that require attention, such as recent developments in the Middle East or wildfires across the country, means there is no slow period in government. 'The pace of events when one is in public life today is beyond dizzying,' he said. In addition to negotiating defence issues with the Europeans and trade matters with Mr. Trump, Mr. Carney's pledge to release a 2025 budget shortly after Parliament resumes means the traditional prebudget lobbying and consultation will run through the summer. Explainer: What federal Bill C-5, the One Canadian Economy Act, is all about Mr. MacKinnon boasted that the Liberals accomplished a lot in a short period, listing the adoption of tax cuts, billions of dollars more for the military and the passing of Bill C-5. In addition to C-5, the House of Commons adopted two bills related to approving government spending. However, other legislation related to border security and tax cuts did not get through the House. Both bills contain elements that are drawing strong criticism from privacy advocates. The tax measures, including an income-tax cut and removing the federal fuel charge, can still go ahead, however, because they were approved in an earlier vote. The government treats tax changes as if they are in place once legislation has received an initial vote of support. Bill C-5 is widely expected to be approved by the Senate next week. Conservative House Leader Andrew Scheer said Mr. Carney has not delivered on his campaign pledges to curb government spending, which is why his party voted against two spending bills this week. 'Maybe he gets some points for new rhetoric, but so far, it's pretty much the same Liberal approach on borrowing, spending, talking down our energy sector, refusing to commit to new big energy projects and defending the Liberal crime policies,' he said in an interview Friday. 'Nothing's off the table': AFN warns of potential legal action if Bill C-5 passes The Conservatives supported C-5 and Mr. Scheer said the party will continue to vote in favour of measures if they involve lower taxes or improving the economy. 'If the government is serious about meeting those objectives, we work with them. And if they don't, then we oppose,' he said. Bloc Québécois Leader Yves-François Blanchet predicted this week that when the Conservatives return in the fall, after party leader Pierre Poilievre is expected to regain a seat via a summer by-election, the party will be less likely to support the Liberals in the House. 'At a certain point, the Conservatives will return to being Conservatives,' he said at a news conference Wednesday, adding that the Liberals will then be more dependent on Bloc support. NDP interim leader Don Davies said that the Liberals under Mr. Carney are adopting more conservative policies. 'So far, I think the empirical evidence from the Carney government is absolutely that they're a right of centre government,' he said in an interview Friday. 'I mean, the first three things that Mr. Carney did was he ripped three policies directly out of the Conservative playbook. He cancelled the carbon tax, he cancelled the capital-gains inclusion policy and he indicated he was going to cut public service jobs,' he said. Having been reduced to just seven seats in the April election, the NDP no longer has party status and is not invited to the weekly meetings of House leaders that sets the parliamentary agenda. Nonetheless, Mr. Davies said his party has been effective at securing amendments to government legislation and bringing public attention to issues such as wildfires in Western Canada.